Biogen Alzheimer’s Drug Slowed Cognitive Decline 38% After Two Years
New trial data showed the lowest dose of Biogen’s experimental anti-tau drug slowed cognitive decline in early Alzheimer’s patients by 38% after two years.
By Deena BeasleyThe lowest dose of Biogen's NASDAQ:BIIB experimental drug that cuts levels of toxic tau protein in the brain slowed cognitive decline in early Alzheimer's patients by 38% after two years, according to new trial data presented on Tuesday.The follow-up data shows that the benefit of t…